Could a bone drug halt skeletal damage in kids with rare disease?

This study tested a drug called denosumab in 15 children aged 4 to 14 with fibrous dysplasia, a rare bone disease that causes weak spots and fractures. The goal was to see if the drug could stop bone lesions from growing during childhood. Participants received injections every 4 weeks for 48 weeks and were monitored with scans and blood tests.